All In Biotech

Drug Trial Radar · NCT06365424

Fenofibrate in Patients With Primary Biliary Cholangitis (PBC)

An Open Label Long-Term Study to Evaluate the Safety and Effectiveness of Fenofibrate in Subjects With Primary Biliary Cholangitis (PBC)

Last checked: Nov 20, 2026Latest source record: Oct 30, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 117 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

117

Planned (sponsor's estimate)

Start

Apr 8, 2017

Primary completion

Apr 2027

Study completion Apr 2027

Sponsor

Lead sponsor
Xijing Hospital of Digestive DiseasesAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Apr 15, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2 / Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

An Open Label Long-Term Study to Evaluate the Safety and Effectiveness of Fenofibrate in Subjects with Primary Biliary Cholangitis (PBC)

Conditions

  • Primary Biliary Cholangitis

Interventions

  • FenofibrateDrug

    Fenofibrate (200 mg/day)

  • UDCADrug

    Ursodeoxycholic acid (13-15 mg/kg/day)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Treatment emergent adverse events (TEAEs)Time frame: Through study completion, up to 120 Months
  2. Percentage of patients with biochemical responseTime frame: Through study completion, up to 120 Months

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Xijing Hospital

    Xi'an, Shaanxi, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.